Depo-Provera lawsuits center on claims that repeated use of the birth control shot may raise the risk of intracranial meningioma. Plaintiffs say Pfizer and related companies failed to provide an adequate warning about this possible risk. Federal cases now sit in multidistrict litigation known as MDL No. 3140 in the Northern District of Florida. Court records show that a settlement program also exists for a large share of current plaintiffs, but it does not cover every case.
Medical research has added weight to the debate. Studies have found an association between injectable medroxyprogesterone acetate, the active drug in Depo-Provera, and meningioma risk, especially after longer use. FDA-approved U.S. labeling now includes a specific meningioma warning. None of these facts prove that Depo-Provera caused a tumor in one person. Each lawsuit still depends on exposure records, diagnosis, medical evidence, state law, and other facts.
Where the Depo-Provera Lawsuit Stands Now
Federal Depo-Provera cases remain part of In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140. Judge M. Casey Rodgers oversees the litigation in Pensacola, Florida. Federal judges use an MDL to handle shared discovery, expert questions, and other common issues in similar lawsuits. An MDL is not the same as a class action. Each plaintiff keeps an individual claim.
An August 10, 2026 court order reported 6,289 pending cases in the MDL. That same order confirmed that plaintiffs’ lead counsel and Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC had entered a settlement program under an agreement dated July 22, 2026. Court language says the program will offer a “substantial percentage” of plaintiffs with pending MDL cases an opportunity to resolve their claims. Defendants did not admit fault or liability as part of the deal.
| Key point | Current information |
|---|---|
| Federal litigation | MDL No. 3140 |
| Court | U.S. District Court, Northern District of Florida |
| Judge | M. Casey Rodgers |
| Pending cases reported Aug. 10, 2026 | 6,289 |
| Settlement agreement date | July 22, 2026 |
| Settlement administrator | BrownGreer PLC |
| Registration deadline stated by court | November 30, 2026 |
| Next listed case management conference | September 18, 2026 |
BrownGreer PLC serves as the settlement administrator. Current court documents state that eligible claimants must register for the settlement program by November 30, 2026. Eligibility rules matter because people who do not settle, people who do not qualify, and certain new plaintiffs may continue through a separate litigation path.
Depo-Provera Lawsuit Timeline
Federal Depo-Provera litigation has moved through several major stages since the cases were combined into MDL No. 3140. Court orders now confirm a settlement program for a large share of pending plaintiffs, along with separate procedures for claims that continue through litigation. Key dates below show how the federal case has developed.
| Date | Depo-Provera Lawsuit Development |
|---|---|
| February 7, 2025 | Federal Depo-Provera cases were centralized in MDL No. 3140 in the Northern District of Florida for coordinated pretrial proceedings. |
| July 22, 2026 | Plaintiffs’ lead counsel and Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC entered a settlement agreement covering a substantial percentage of pending claims. |
| August 5, 2026 | BrownGreer PLC was appointed as the settlement administrator to help manage the settlement program. |
| August 10, 2026 | Case Management Order No. 14 reported 6,289 pending cases and set procedures for claims that remain outside the settlement program. |
| September 18, 2026 | A case management conference and Rule 702 hearing were scheduled to address expert testimony and other litigation issues. |
| November 30, 2026 | Court records list this date as the registration deadline for eligible claimants who want to participate in the settlement program. |
Settlement participation does not end every Depo-Provera case. Plaintiffs who do not qualify, choose not to settle, or bring certain later claims may continue under separate MDL procedures. Pfizer and the related defendants have not admitted fault or liability as part of the settlement agreement.
What the Depo-Provera Lawsuits Allege
Plaintiffs claim that Depo-Provera and other depot medroxyprogesterone acetate injections may cause or contribute to intracranial meningiomas. Their lawsuits focus heavily on the warnings given to doctors and patients. They argue that drug makers knew, or should have known, about the possible risk and did not provide enough information before treatment. Claims can involve failure to warn, negligence, defective design, and other product liability issues under state law.
Pfizer and the other defendants deny liability and maintain that the medication is safe and effective when used as directed. Each plaintiff still has to prove more than simple Depo-Provera use. Medical records, treatment history, tumor diagnosis, and other evidence must support the claim. Court filings also discuss Depo-subQ Provera 104, a lower-dose version given under the skin, but those allegations remain disputed and do not amount to a court finding that one version was safer or that another caused a specific injury.
What Research Says About Depo-Provera and Meningioma Risk
A 2024 study published in The BMJ drew major attention to a possible link between injectable medroxyprogesterone acetate and intracranial meningioma. Researchers compared 18,061 women who had surgery for meningioma with 90,305 women in a control group. They reported an odds ratio of 5.55 for injectable medroxyprogesterone acetate, with the higher risk mainly seen after use of one year or longer. That number does not mean every Depo-Provera user has a 5.55 times greater absolute chance of developing a tumor. The study found an association, and the number of exposed women in this part of the research was small.
U.S. research has also reported a higher meningioma risk among users of injectable medroxyprogesterone acetate. One large insurance-based study found 53% higher odds of meningioma overall and 68% higher odds of cerebral meningioma, with risk rising after longer exposure. Another U.S. analysis reported a relative risk of 2.43 and found the strongest association among people who used the drug for more than four years or started after age 31. These findings may support expert arguments in the litigation, but they do not prove that Depo-Provera caused a tumor in every individual case.
FDA Adds Meningioma Warning to Depo-Provera Label
FDA-approved prescribing information for Depo-Provera now includes a specific warning about meningioma. Section 5.4 states that cases have been reported after repeated use of medroxyprogesterone acetate, mainly after long-term exposure, and advises healthcare professionals to monitor patients for possible symptoms and stop Depo-Provera CI if a meningioma is diagnosed. The FDA listed this as a major labeling change in December 2025. Depo-Provera CI also carries a separate boxed warning about bone mineral density loss and is generally not recommended for use beyond two years unless other birth control options are considered inadequate. The updated warning adds important safety information, but it does not prove that the drug caused a tumor in any individual lawsuit.
How Meningioma Can Affect Health
Meningioma develops in the meninges, the layers of tissue that cover the brain and spinal cord. Most grade 1 tumors grow slowly, but their location can still cause serious problems if they press on the brain, nerves, blood vessels, or nearby structures. Higher-grade tumors can act more aggressively. Symptoms may include headaches, seizures, confusion, vision problems, or loss of hearing or smell, although these signs can also come from other conditions.
Treatment depends on the tumor’s size, location, grade, growth, and the patient’s symptoms. Doctors may recommend regular scans, surgery, radiosurgery, or radiation therapy. A benign meningioma can still require major treatment and may cause lasting effects, especially when it affects important parts of the brain or nearby nerves.
What Can Affect Depo-Provera Lawsuit Eligibility
Past use of the contraceptive shot alone does not establish a lawsuit. Current federal litigation focuses on people who allege that an MPA product caused an intracranial meningioma. Exposure length, diagnosis date, tumor type, product identity, and state filing rules can all affect a legal review.
Useful evidence often includes:
- Depo-Provera or generic MPA injection records
- Pharmacy, clinic, insurance, or billing records
- MRI or CT reports that document the tumor
- Neurosurgery and hospital records
- Pathology reports if tissue was removed
- Dates of the first and last injections
- Details about other hormone medicines
- Medical bills and evidence of future care
- Employment records if the condition caused lost income
Federal court procedures show how important this documentation has become. Case Management Order No. 14 requires litigating plaintiffs to provide a fact sheet and documents that establish use of an MPA product. Court rules also require information about the first and last dates of use and proof tied to the claimed injury.
Missing old pharmacy records do not always end a possible case, but gaps can make proof harder. Clinics, insurers, prior doctors, hospital systems, and pharmacy databases may hold records that a lawyer can request.
How Much Could a Depo-Provera Settlement Be Worth?
No official average Depo-Provera settlement amount has been announced. Current reports confirm a settlement program, but individual payouts and compensation tiers have not been made public. Legal websites estimate possible values from about $75,000 to more than $1 million, depending on the case. These figures are only projections, not guaranteed amounts.
Actual compensation may depend on tumor severity, surgery, long-term care, seizures, vision or hearing loss, lost income, medical costs, disability, and the strength of the evidence. Until official payout details become public, any settlement range should be treated as an estimate.
Filing Deadlines Can Still Affect New Depo-Provera Claims
The settlement program does not mean every future Depo-Provera lawsuit has ended. Case Management Order No. 14 recognizes certain “Future Filed Plaintiffs,” including cases filed, removed, refiled, or transferred into the MDL after August 10, 2026. Those plaintiffs may still continue with litigation, but they must meet specific court rules and provide required evidence.
Settlement deadlines are also different from statutes of limitations. State law controls many filing deadlines, and the rules can vary depending on where a claim is filed. The diagnosis date, the date a person learned about a possible link to Depo-Provera, and other facts may affect when the legal deadline starts.
Timing has already become an important issue in the MDL. A future-filed plaintiff who claims a meningioma developed before March 27, 2024 must explain why the case is not barred by the applicable statute of limitations. Waiting too long can therefore put a claim at risk, so anyone with deadline concerns should get advice based on the law that applies to their case.
Depo Provera MDL Is Not a Class Action
MDL No. 3140 combines federal cases for pretrial management. It does not turn thousands of people into one plaintiff. Each person keeps a separate case, medical history, damages claim, and legal rights.
Centralization can still have a large effect. One judge can decide shared questions about scientific experts, causation, discovery, and legal defenses. Current court scheduling lists a Rule 702 hearing for September 18, 2026, after the next case management conference. Rule 702 governs the admissibility of expert testimony in federal court, so expert evidence remains an important part of claims that continue outside the settlement process.
Settlement participation is also different from winning a trial. Pfizer and related defendants did not admit liability under the current settlement agreement, and plaintiffs who remain in litigation still face proof requirements and possible defenses.
What to Know After a Meningioma Diagnosis
Someone diagnosed with meningioma after Depo-Provera use should first collect clear medical and treatment records. Injection dates, pharmacy or clinic records, MRI reports, diagnosis details, treatment history, and any lasting symptoms can all help show the full picture. Patients who still use Depo-Provera should also discuss future doses and other birth control options with their healthcare provider.
Legal review is a separate step. Product type, length of use, diagnosis date, state filing deadlines, settlement rules, and prior medical history can all affect a claim. An online eligibility form cannot decide those issues on its own, so case-specific legal advice may be needed.
Conclusion
Depo-Provera litigation has moved beyond the early filing stage. Federal court records now confirm thousands of claims, a July 2026 settlement program, a November 30 registration deadline for eligible participants, and a separate path for cases that remain in litigation. Scientific studies have also reported an association between prolonged injectable medroxyprogesterone acetate use and meningioma, and FDA labeling now carries a specific warning about that risk.
Those developments do not guarantee compensation. A viable claim still depends on documented drug exposure, a confirmed diagnosis, causation evidence, legal deadlines, and the facts of the individual case. Medical concerns should go to a qualified healthcare professional, and personal lawsuit questions should go to a licensed product liability attorney. This material provides general information and does not serve as medical or legal advice.
Common Questions
A settlement program now exists for a substantial share of claims in the federal MDL. Court records state that an agreement dated July 22, 2026 covers certain pending cases, but it does not resolve every lawsuit. Pfizer and the related defendants also did not admit fault or liability as part of the agreement.
Generic medroxyprogesterone acetate products also appear in the federal litigation, but eligibility depends on more than the drug name. Product manufacturer, treatment history, diagnosis, state law, and the legal theory used in the claim can all matter. A past injection alone does not establish liability.
Meningioma does not always mean brain cancer. Grade 1 meningiomas are usually low-grade tumors and often grow slowly, while higher-grade tumors can act more aggressively. Even a noncancerous tumor can cause serious health problems if it presses on the brain, nerves, or nearby structures.
Headaches alone do not establish a meningioma claim. Current federal cases focus on people with a diagnosed intracranial meningioma and a history of relevant drug exposure. Medical records, imaging, diagnosis details, and treatment history are much more important than one symptom on its own.
Past use can still be relevant even if the injections stopped before the diagnosis. Filing rights may depend on exposure length, diagnosis date, when the possible connection became known, and the statute of limitations that applies in the person’s state. Those deadlines can differ from the settlement registration deadline.
